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Idiopathic pleuroparenchymal ﬁbroelastosis is a rare idiopathic interstitial pneumonia. It was ﬁrst
described in 2004 and subsequently included in the ATS/ERS classiﬁcation of idiopathic interstitial
pneumonia in 2013. There have been few cases reported so far. The diagnostic criteria is still emerging
and its etiology is being questioned. We report a case of pleuroparenchymal ﬁbroelastosis probably
idiopathic, the ﬁrst of its kind to be reported from India, and a brief review of the literature.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Idiopathic pleuroparenchymal ﬁbroelastosis is a chronic idio-
pathic interstitial pneumonia, characterised by upper lobe pre-
dominance, signiﬁcant involvement of the pleura and a
histopathology revealing subpleural ﬁbroelastosis. It was ﬁrst
described in 2004 and subsequently included in the ATS/ERS clas-
siﬁcation of Idiopathic Interstitial Pneumonia (IIP) in 2013 under
the category of rare IIP's. Sporadic cases and few series have been
reported from all across the globe, but none of these have been
from India. We report a case of pleuroparenchymal ﬁbroelastosis
probably idiopathic, the ﬁrst of its kind from India.2. Case description
A 41 year old lady presented with dry cough and progressive
breathlessness for a year. She was evaluated in another centre with
a CT thorax and VATS biopsy 3 months into illness. This showed
ﬁbrosing interstitial pneumonia (the slides reviewed in our centre
was reported as organizing pneumonia). Post biopsy, she developedMedicine, Christian Medical
m (B. Thangakunam),
djchris@cmcvellore.ac.in
Burad).
Ltd. This is an open access article ua left sided loculated pneumothorax, and this remained even after
intercostal drainage. She was treated with oral corticosteroids. Af-
ter a brief period of stability, her symptoms continued to progress.
Azathioprine was added on for another 3 months with no response
and hence stopped. She was then brieﬂy initiated on Pirfenidone,
which was stopped due to intolerance. When she presented to us,
she was only on oral steroids. In the mean time, she developed a
spontaneous pneumothorax on right side which completely
resolved with intercostal tube drainage. There was no history
suggestive of a connective tissue disorder. Her co-morbidities were
type 2 diabetes mellitus, hypothyroidism and primary infertility.
On examination, she was not clubbed. She had reduced air entry in
the left infraclavicular region and bilateral diffuse crackles and
squeaks. Her room air saturation was 95% but she quickly desatu-
rated to 82% on exertion. Her ABG revealed chronic type 2 respi-
ratory failure with hypoxia. Her CT scan (Fig. 1) revealed loculated
pneumothorax in left upper zone, pleural and subpleural paren-
chymal ﬁbrosis with upper lobe predominance. The ﬁbrotic
changes have signiﬁcantly worsened compare to previous CT
picture.
The differentials considered were idiopathic pulmonary ﬁbrosis,
idiopathic pleuroparenchymal ﬁbroelastosis and chronic hyper-
sensitivity pneumonitis. Absence of response to steroids and
absence of triggering factors dissuaded a diganosis of chronic hy-
persensitivity pneumonitis. She was started on the maximum
tolerable dose of Pirfenidone(400 mg thrice a day) and the oralnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The chest x-ray and CT thorax revealed a left loculated pneumothorax, pleural and subpleural parenchymal ﬁbrosis with upper lobe predominance and apical pleural
thickening.
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bilitation. She was also initiated on nocturnal Non-invasive Venti-
lation (NIV) at IPAP (Inspiratory Positive Airway Pressure) of 15 cm
of H2O and EPAP (Expiratory Positive Airway Pressure) of 6 cm of
H2O and long term oxygen therapy was initiated at 1 L/min. She re-
presented with increasing shortness of breath, coughwith purulent
expectoration and pleuritic right sided chest pain. A CTPAwas done
to rule out a pulmonary embolism and revealed new areas of
bilateral ground glass opacities. She was initiated on intravenous
antibiotics. After an improvement for few days, she deteriorated
with reduced sensorium secondary to worsening type 2 respiratory
failure. Her supports on the NIV were increased. She succumbed to
her illness in the next couple of days.
An autopsy was performed. The pleura appeared ﬁbrotic and
adherent to the underlying lungs. The right and left lungs were
contracted and weighed 250 g and 335 g, respectively. Serial
sectioning revealed areas of consolidation and ﬁbrosis. On histo-
pathological examination (Fig. 2), there was marked pleural ﬁbrosis
and elastosis with involvement of the underlying lung parenchyma.
There was interstitial ﬁbrosis and elastosis with some of the alveoli
displaying type 2 pneumocyte hyperplasia. Overall, the features
were in keeping with pleuroparenchymal ﬁbroelastosis. As there
were no precipitating factors, we concluded her to have had Idio-
pathic Pleuroparenchymal Fibroelastosis (IPPFE).
The various differentials considered were discussed with the
patient and her husband. A few uncoventional treatments were
given with good intentions (Pirfenidone for possible idiopathic
pulmonary ﬁbrosis and NIV for type 2 respiratory failure in the
presence of a loculated pneumothorax), and these were discussed
with the family prior to initiation.
3. Discussion
IPPFE is a rare and relatively new entity, ﬁrst coined in 2004 byFrankel et al. [1], based on 5 patients identiﬁed between 1996 and
2001. Cases with similar description have been mentioned in the
literature since 1992, especially from Japan. IPPFE was included in
the new ATS/ERS classiﬁcation of Idiopathic Interstitial Pneumonia
(IIP) published in 2013 [2] under the rare IIP's. Including the ﬁrst
report in 2004, there have been 36 cases reported so far. Thirty
cases have been elaborated in the case series and literature review
published by Rosenbaum et al., in 2015 [3]. But among these, a case
series of 4 patients from von der Thusen et al. [4] clearly describe
PPFE secondary to bone marrow transplantation and hence cannot
be counted as IPPFE. We identiﬁed 10 additional cases of IPPFE, half
of these published in four different reports [5e8] in 2014 and 2015
and the other half in a single series in 2012 by Kusagaya et al. [9].
Nevertheless, none have been reported from India.
Chronic cough and shortness of breath are the usual symptoms
of these patients, as in other IIP's. It appears that there is an
increased propensity to pneumothorax in IPPFE compared to other
IIP's. Among the cases reported, one patient had a presentation
with recurrent pneumothorax [6]. There was another presentation
with secondary spontaneous pneumothorax [10] published by
Becker et al. This publication had a second case of IPPFE which had
a persistent pneumothorax after a VATS biopsy, as in our case. Both
the cases published by Redondo et al. [8] were complicated by a
pneumothorax post CT guided biopsy. It has been suggested that
the increased deposition of elastin ﬁbres in the lung is responsible
for the easy development of pneumothorax. In an excellent com-
parison with IPF which is a close clinical differential for IPPFE, as in
our case, Enomoto et al. [11] elucidated a lower incidence of the ﬁne
crackles, more pneumothoraces, a higher proportion of never-
smokers, and lower body mass indices in patients with IPPFE. Our
patient does have all these characteristics.
The largest series published so far (12 cases), in 2012 by Reddy
et al. [12] and the recent series with literature review by Rose-
nbaum et al. [3], contend the etiology in the cases of PPFE usually
Fig. 2. (a) Subpleural ﬁbrosis and elastosis with extension into the pulmonary parenchyma; H&E 50x. (b) Interstitial ﬁbrosis with elastosis and type 2 pneumocyte hyperplasia; H&E
200x. (c)Interstitial ﬁbrosis with elastosis; H&E 400x. (d) Orcein stain showing numerous elastic ﬁbres in the pleural tissue extending into the adjacent parenchyma. 50x.
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various cases are genetic, familial, autoimmune, recurrent in-
fections and drug induced including chemotherapeutic agents. A
review published in 2013 by von der Thusen [13], looked at 78 casesTable 1
Survival details of all patient with IPFFE published so far.
Sl. No. Author Duration from
time of report
Years
1. Frankel et al. [1] 12
2. 7
3. 7
4. 2
5. 5
6. Piciucchi et al. [14] 3
7. Reddy et al. [12] 2
8. 4
9. 6
10. 2
11. 3
12. 3
13. 5
14. 6
15. 4
16. 8
17. 4
18. 5
19. Kusagaya et al. [9] 1
20. 0
21. 3
22. 0
23. 1
24. Noh et al. [6] 3
25. Cuppens et al. [7] 2
26. Rosenbaum et al. [3] 1
27. 7
28. 2
29. 9
30. Redondo et al. [8] 7
31. Our case 1of PPFE published till then. The etiology in just over half of these
patients was either post lung transplantation or bone marrow
transplantation highlighting the commonest cause of PPFE. In the
other half of these patients who have been thought to have IPPFE,onset of symptoms to
or death
Alive(A) or Dead(D) at time of report
Months
0 A
0 A
0 A
0 D
0 D
0 A
0 A
0 A
4 D
7 A
6 D
0 A
0 A
0 D
0 A
0 A
0 D
5 D
0 A
6 A
8 A
10 A
4 A
1 A
6 A
2 D
0 A
0 A
0 D
10 A
3 D
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The review by von der Thusen [12], also set out separate HRCT
and pathological criteria for PPFE and classiﬁed them as ‘deﬁnite’
and ‘consistent with’. Our patient would classify into ‘deﬁnite PPFE’
based on HRCT ﬁndings of upper lobe pleural thickening, sub-
pleural ﬁbrosis and less marked involvement of the lower lobes.
The differential diagnosis for these HRCT features would usually
include asbestosis, advanced chronic ﬁbrotic sarcoidosis and drug
induced lung disease. The histopathology is crucial is concluding
the diagnosis of PPFE. Rosenbaum et al. [3] in a more recent pub-
lication, in addition to proposing that PPFE is secondary to chronic
lung injury rather than a separate entity, have laid down proposed
diagnostic criteria, based on their series of 5 cases and few of the
earlier reports. These are: (1) Fibrous interstitial pneumonia with
>80% ﬁbroelastic changes in nonatelectatic (collapsed) lung, (2)
Subpleural and/or centrilobular distribution, (3) Overall inﬂam-
mation absent to mild, (4) No speciﬁc lobe predilection, typically
multilobar and (5) Rare or no granulomas. These are different from
those followed so far, and are yet to be validated and considered by
others.
The deﬁnitive treatment for IPPFE is lung transplantation. Most
patients are tried with steroids [3] and some have tried other im-
munosuppressants in addition. In our patient, we also tried Pirfe-
nidone due to the clinical possibility of Idiopathic Pulmonary
Fibrosis. Prognosis of patients with IPFFE is variable. Piciucchi et al.
[14] observed that there could be two forms of IPFFE, looking at the
cases published between 2004 and 2008. These they termed as a
sporadic form and a familial form, the latter being more aggressive.
But this has not been talked of since. We have tabulated (Table 1)
the survival details of all the patients published so far, as mentioned
in each of the reports. Six of the 36 patients did not have details on
the duration of symptoms.
4. Conclusion
IPPFE is a rare IIP, but more cases have been reported in the last
few years. It is being debated if there are speciﬁc etiologies in these
cases. Newer diagnostic criteria are being proposed and need
validation and acceptance. Treatment options are limited and
prognosis is poor.We report this case of PPFE of probably idiopathic
origin, the ﬁrst of its kind from India, which will add to number of
global cases reported and will help in establishing the above, more
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